Nabi Names Thomas McLain Chief Operating Officer

McLain to Spearhead Company's Growth; Mark Smith Becomes Chief

Financial Officer



Apr 02, 2001, 01:00 ET from Nabi

    BOCA RATON, Fla., April 2 /PRNewswire/ -- Nabi (Nasdaq:   NABI) today
 announced the promotion of Thomas H. McLain to the position of Executive Vice
 President and Chief Operating Officer of the company.  Mr. McLain was formerly
 Senior Vice President, Corporate Services and Chief Financial Officer of Nabi.
 Mr. McLain will also be proposed as a member of the Board of Directors at the
 May Annual Meeting of Shareholders.  The company also announced the promotion
 of Mark Smith, formerly Nabi's Vice President, Finance, to Senior Vice
 President, Finance and Chief Financial Officer.
     David J. Gury, Chairman, President and Chief Executive Officer said, "We
 are taking this critical step in Nabi's development to align our operations
 and plans for driving future growth under Tom's capable direction.  Tom has
 already worked successfully to strengthen the company's financial position and
 to develop the finance, information technology, human resources and legal
 functions to support Nabi's growth.  He will now add sales, marketing,
 manufacturing and business development to his responsibilities."
     Mr. McLain commented, "Our clear priority is to maintain the growth of our
 existing biopharmaceutical product business and to prepare the way for the
 launch of the new, proprietary products emerging from our development
 pipeline. We have an immediate goal of finalizing a business partner for our
 Nabi(R) StaphVAX(R) program and moving this program forward as expeditiously
 as possible. In addition, we are preparing to bring our Boca manufacturing
 plant on line this year and are taking steps to build value in our antibody
 business.
     Nabi, a vertically integrated biopharmaceutical company, has a broad
 product portfolio and significant R&D capabilities focused on the development
 and commercialization of drugs that prevent and treat infectious and
 autoimmune diseases. Nabi currently has several clinical trials underway in
 these areas as well as four marketed biopharmaceutical products. Nabi has its
 corporate headquarters in Boca Raton, Florida, with principal R&D offices and
 laboratories in Rockville, Maryland. Additional information about Nabi may be
 obtained on the Company's website at: www.nabi.com.
     This press release contains forward-looking statements that reflect the
 Company's current expectations regarding future events.  While these
 statements reflect the Company's best current judgment, they are subject to
 risks and uncertainties.  Actual results may differ significantly from the
 results projected herein due to a number of factors, including, but not
 limited to, the need for additional financing and access to capital; the costs
 of research and development; dependence upon third parties to manufacture
 product; the impact on the Company of current industry supply and demand
 factors and the supply of and demand for the Company's individual products;
 margin pressure on the Company's non-specific antibody product line; future
 sales growth prospects for its biopharmaceutical products; the likelihood that
 any product in the research pipeline can receive regulatory approval in the
 U.S. or abroad or be successfully developed, manufactured and marketed; and
 failure to receive licensure for the Boca Raton manufacturing facility.  These
 factors are more fully discussed in the Company's most recent Form 10-K filed
 with the Securities and Exchange Commission.
 
 

SOURCE Nabi
    BOCA RATON, Fla., April 2 /PRNewswire/ -- Nabi (Nasdaq:   NABI) today
 announced the promotion of Thomas H. McLain to the position of Executive Vice
 President and Chief Operating Officer of the company.  Mr. McLain was formerly
 Senior Vice President, Corporate Services and Chief Financial Officer of Nabi.
 Mr. McLain will also be proposed as a member of the Board of Directors at the
 May Annual Meeting of Shareholders.  The company also announced the promotion
 of Mark Smith, formerly Nabi's Vice President, Finance, to Senior Vice
 President, Finance and Chief Financial Officer.
     David J. Gury, Chairman, President and Chief Executive Officer said, "We
 are taking this critical step in Nabi's development to align our operations
 and plans for driving future growth under Tom's capable direction.  Tom has
 already worked successfully to strengthen the company's financial position and
 to develop the finance, information technology, human resources and legal
 functions to support Nabi's growth.  He will now add sales, marketing,
 manufacturing and business development to his responsibilities."
     Mr. McLain commented, "Our clear priority is to maintain the growth of our
 existing biopharmaceutical product business and to prepare the way for the
 launch of the new, proprietary products emerging from our development
 pipeline. We have an immediate goal of finalizing a business partner for our
 Nabi(R) StaphVAX(R) program and moving this program forward as expeditiously
 as possible. In addition, we are preparing to bring our Boca manufacturing
 plant on line this year and are taking steps to build value in our antibody
 business.
     Nabi, a vertically integrated biopharmaceutical company, has a broad
 product portfolio and significant R&D capabilities focused on the development
 and commercialization of drugs that prevent and treat infectious and
 autoimmune diseases. Nabi currently has several clinical trials underway in
 these areas as well as four marketed biopharmaceutical products. Nabi has its
 corporate headquarters in Boca Raton, Florida, with principal R&D offices and
 laboratories in Rockville, Maryland. Additional information about Nabi may be
 obtained on the Company's website at: www.nabi.com.
     This press release contains forward-looking statements that reflect the
 Company's current expectations regarding future events.  While these
 statements reflect the Company's best current judgment, they are subject to
 risks and uncertainties.  Actual results may differ significantly from the
 results projected herein due to a number of factors, including, but not
 limited to, the need for additional financing and access to capital; the costs
 of research and development; dependence upon third parties to manufacture
 product; the impact on the Company of current industry supply and demand
 factors and the supply of and demand for the Company's individual products;
 margin pressure on the Company's non-specific antibody product line; future
 sales growth prospects for its biopharmaceutical products; the likelihood that
 any product in the research pipeline can receive regulatory approval in the
 U.S. or abroad or be successfully developed, manufactured and marketed; and
 failure to receive licensure for the Boca Raton manufacturing facility.  These
 factors are more fully discussed in the Company's most recent Form 10-K filed
 with the Securities and Exchange Commission.
 
 SOURCE  Nabi